根據 位華爾街分析師的預測,ProUroCare Medical Inc 的收入預期範圍從 $ 到 $
ProUroCare Medical Inc 的盈利品質評分是多少?
ProUroCare Medical Inc 的盈利品質評分為 B+/46.87752。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
ProUroCare Medical Inc 何時發布財報?
ProUroCare Medical Inc 的下一份財報預計在 發布
ProUroCare Medical Inc 的預期收益是多少?
根據華爾街分析師的預測,ProUroCare Medical Inc 的預期收益為 $
ProUroCare Medical Inc 是否超出收益預期?
ProUroCare Medical Inc 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.0001
開盤價
$0.0001
當日範圍
$0.0001 - $0.0002
52週區間
$0.0001 - $0.005
交易量
26.1K
平均成交量
1.8K
股息收益率
--
每股盈餘 (TTM)
-0.14
市值
$1.8K
什麼是 PUMD?
ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.